We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Maturing biotechs turn to pharma's markets.
- Authors
Ratner, Mark
- Abstract
The article reports that the nature of early biotech specifically the development of recombinant proteins to replace or augment the body's natural protein production and disease-fighting capability, has lent itself to niche applications in severe or life-threatening conditions. Moreover, market regulators have been more forgiving of safety issues when it comes to severe diseases with no alternative therapies. Sepracor Inc. is one example of this phenomenon. Pleased with Sepracor's 2004 results and its anticipated launch in the first quarter of 2005 of one of biotech's rare mass-market drugs, investors have bid up the firm's stock to near three-year highs.
- Subjects
BIOTECHNOLOGY industries; MEDICAL technology; MEDICAL research; THERAPEUTICS; SEPRACOR Inc.; INVESTORS; INVESTMENTS
- Publication
Nature Biotechnology, 2005, Vol 23, Issue 3, p269
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0305-269